ScinoPharm Taiwan, Ltd. · TWSE:1789
ScinoPharm Taiwan — Q1 2012 Earnings Presentation
26 slides from ScinoPharm Taiwan's earnings presentation, July 2012
Slide 1: ScinoPharm Management Presentation
ScinoPharm Management Presentation TWSE 1789 July, 2012 1
Slide 2: Disclaimer
Confidential Disclaimer This material has been prepared by ScinoPharm Taiwan, Ltd. (“ScinoPharm”). Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information cont
Slide 3: Table of Content
Confidential Table of Content Overview of ScinoPharm Financial & Operation Results China Market Business Outlook Q&A 3
Slide 4: Overview of ScinoPharm
Overview of ScinoPharm - An Active Pharmaceutical Ingredient Company 4
Slide 5: Company Overview
Confidential Company Overview Maintain dominant position in Specialty APIs for generic market. Established strong presence in US/EU generic market, some channeled through Indian generic companies. Aggressively developing Japanese and Chinese markets Developed more than 50 generic APIs with 17 launch
Slide 6: ScinoPharm Changshu
Confidential ScinoPharm Changshu Construction completed Administration Production Building Building I Utility Utility Fire Fighting Building I Building II Pump Room R&D Building Solid Waste WWTP Production Storage Area Warehouse I Building II Warehouse II 6
Slide 7: ScinoPharm Changshu vs Tainan
Confidential ScinoPharm Changshu vs Tainan Identical Same plant site size (6.6 hectares) API R&D capabilities (R&D staff >100 people) International GMP standards Advanced EHS standards Global registrations & markets (incl. China) Successful GMP inspections by agencies from regulated markets (incl. U
Slide 8: ScinoPharm - Oncological API Leader
Confidential ScinoPharm - Oncological API Leader 8
Slide 9: Financial & Operation Results
Financial & Operation Results 9
Slide 10: P&L - Consolidated
Confidential P&L - Consolidated Q1,’12 Q4,’11 Q1,’11 NT$MM, except EPS (reviewed) (audited) (reviewed) QoQ YoY Net Sales 971 1,130 796 -14% 22% Gross Profit 523 597 370 -12% 41% Gross margin 54% 53% 47% Operating Expense (239) (251) (180) -5% 33% Operating Income 284 346 190 -18% 49% Operating margi
Slide 11: Balance Sheet- Consolidated
Confidential Balance Sheet- Consolidated NT$MM 2012/03/31 2011/03/31 (reviewed) (reviewed) Cash and Cash Equivalents 3,236 33% 1,989 27% Accounts Receivable 740 8% 597 8% Inventories 1,801 18% 1,424 19% Long-Term Investments 150 2% 218 3% Fixed Assets 3,291 34% 2,833 38% Total Assets 9,689 100% 7,42
Slide 12: Cash Flows- Consolidated
Confidential Cash Flows- Consolidated Q1, 2012 Q1, 2011 NT$MM (reviewed) (reviewed) Cash and cash equivalents at 3,294 1,908 beginning of year Cash flows from operating activities 147 218 CAPEX (171) (125) Other Investing activities 34 (12) Cash flows from financing activities - - Cash and cash equi
Slide 13: Sales by Business
Confidential Confidential Sales by Business 2011Q1 2012Q1 CMO CRO 1% CMO 3% CRO 17% 4% Generic Generic 96% 79% 13
Slide 14: Sales by Indications
Confidential Confidential Sales by Indications 2011Q1 2012Q1 Others, 8% Others, Others 16% Others 29.6% Oncology, Oncology, 37.8% CNS, 74% CNS, 67% 18% 17% 學名藥 90.91% 14
Slide 15: China – Emerging Market for the World
China – Emerging Market for the World 15
Slide 16: China - Top 3 Pharma Market WW
China - Top 3 Pharma Market WW In 2010, China has grown rapidly and became the 3rd largest pharmaceutical market globally, only next to USA and Japan China market will continue to grow at a CAGR of 22% from US$ 41 billion in 2010 to US$ 125 billion in 2015 ScinoPharm Changshu (China) has been establ
Slide 17: Rapidly Rising GMP Standards in China
Confidential Rapidly Rising GMP Standards in China New GMP standards consistent with international standards and emphasize on the facility sophistication Strict requirements on air pressure & isolation in high potency areas Detailed rules on A/C, purified water, packaging systems Rigid equipment qua
Slide 18: Impacts of China’s New GMP
Confidential Impacts of China’s New GMP To consolidate pharma industry, enhance its capabitily, a new version of GMP was issued on March 1, 2011 with a grace period of 5 years 500+ pharma companies in China might not survive Many formulation companies are looking for new-GMP compliant API providers,
Slide 19: Products Matches China’s Demands
Confidential Products Matches China’s Demands 2010 Therapeutic China ScinoPharm’s API Rank Market Indication Candidates Share 1 Anti- 23.7% 3 candidates infective 2 Anti-cancer 10.3% 30 candidates, focus area 3 Cardio- 8.2% 4 candidates vascular 4 Metabolic 7.1% 5 candidates 5 CNS 1.7% 6 candidates
Slide 20: Anti-Cancer Drugs in China
Anti-Cancer Drugs in China Top 20 anti-cancer drugs in China weigh about 74% in value out of total anti-cancer drugs, ScinoPharm has 9 products ready Ranking Drug Market value Oncological drug market in China (RMB bln) 2 grew by 30% in 2010 Docetaxel 1.54 3 Capecitabine 1.14 4 Paclitaxel 1.10 8 Peme
Slide 21: Peer Comparison
Confidential Peer Comparison – Number of Oncological DMFs in China *SPT will proceed to submit DMF applications to the SFDA 21
Slide 22: ScinoPharm’s Strategies – China Market Development
Confidential ScinoPharm’s Strategies – China Market Development API sales Promote APIs made by Taiwan and Changshu plants to local or foreign formulation companies in China Co-Development with Local Formulation Firms Partner with Chinese formulation companies to integrate from APIs to formulations t
Slide 23: Business Outlook
Business Outlook 23
Slide 24: 2012 Product Launch Plan
2012 Product Launch Plan Regional WW Sales API Region Indications Brand Marketer Sales Antithrombotic, $US $US Argatroban US GSK Anticoagulant 139MM* 205MM* Galantamine Alzheimer’s $US $US EU Janssen HBr disease 314MM* 527MM* $US $US Modafinil US Antinarcolepsy Cephalon 1,078MM* 1,182MM* Riluzole $U
Slide 25: Outlook
Confidential Outlook Sustain Leadership Position in Oncological Injectable APIs Continue developing small molecule oncological injectable APIs and expand into other areas with high technology barriers including Peptides Expand Presences in China Expansion of API business to timely capture the Chines
Slide 26: Brand Quality with Asian Advantages
Confidential Brand Quality with Asian Advantages www.scinopharm.com 26